Search Results - "Schneider, Paula A."

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization by Dai, Haiming, Smith, Alyson, Meng, X Wei, Schneider, Paula A, Pang, Yuan-Ping, Kaufmann, Scott H

“…The mechanism by which the proapoptotic Bcl-2 family members Bax and Bak release cytochrome c from mitochondria is incompletely understood. In this paper, we…”
Get full text

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia by Murthy, Guru Subramanian Guru, Saliba, Antoine N, Szabo, Aniko, Harrington, Alexandra, Abedin, Sameem, Carlson, Karen, Michaelis, Laura, Runaas, Lyndsey, Baim, Arielle, Hinman, Alex, Maldonado-Schmidt, Sonia, Venkatachalam, Annapoorna, Flatten, Karen S, Peterson, Kevin L, Schneider, Paula A, Litzow, Mark, Kaufmann, Scott H, Atallah, Ehab

“…Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to…”
Get full text

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells by Schroeder, Barbara, Vander Steen, Travis, Espinoza, Ingrid, Venkatapoorna, Chandra M. Kurapaty, Hu, Zeng, Silva, Fernando Martín, Regan, Kevin, Cuyàs, Elisabet, Meng, X. Wei, Verdura, Sara, Arbusà, Aina, Schneider, Paula A., Flatten, Karen S., Kemble, George, Montero, Joan, Kaufmann, Scott H., Menendez, Javier A., Lupu, Ruth

“…Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted cancer therapies. However,…”
Get full text

Immunodetection of human topoisomerase I-DNA covalent complexes by Patel, Anand G, Flatten, Karen S, Peterson, Kevin L, Beito, Thomas G, Schneider, Paula A, Perkins, Angela L, Harki, Daniel A, Kaufmann, Scott H

“…A number of established and investigational anticancer drugs slow the religation step of DNA topoisomerase I (topo I). These agents induce cytotoxicity by…”
Get full text

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells by Dai, Haiming, Ding, Husheng, Meng, X Wei, Peterson, Kevin L, Schneider, Paula A, Karp, Judith E, Kaufmann, Scott H

“…Mitochondrial outer membrane permeabilization (MOMP), a key step in the intrinsic apoptotic pathway, is incompletely understood. Current models emphasize the…”
Get full text

Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes by Patel, Anand G., Flatten, Karen S., Schneider, Paula A., Dai, Nga T., McDonald, Jennifer S., Poirier, Guy G., Kaufmann, Scott H.

“…Poly(ADP-ribose) polymerase-1 (PARP1) plays critical roles in the regulation of DNA repair. Accordingly, small molecule inhibitors of PARP are being developed…”
Get full text

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors by Venkatachalam, Annapoorna, Correia, Cristina, Peterson, Kevin L, Hou, Xianon, Schneider, Paula A, Strathman, Annabella R, Flatten, Karen S, Sine, Chance C, Balczewski, Emily A, McGehee, Cordelia D, Larson, Melissa C, Duffield, Laura N, Meng, X Wei, Vincelette, Nicole D, Ding, Husheng, Oberg, Ann L, Couch, Fergus J, Swisher, Elizabeth M, Li, Hu, Weroha, S John, Kaufmann, Scott H

“…Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid…”
Get full text

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era by Correia, Cristina, Maurer, Matthew J., McDonough, Samantha J., Schneider, Paula A., Ross, Paige E., Novak, Anne J., Feldman, Andrew L., Cerhan, James R., Slager, Susan L., Witzig, Thomas E., Eckloff, Bruce W., Li, Hu, Nowakowski, Grzegorz S., Kaufmann, Scott H.

“…How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study…”
Get full text

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies by Gupta, Mamta, Hendrickson, Andrea E. Wahner, Yun, Seong Seok, Han, Jing Jing, Schneider, Paula A., Koh, Brian D., Stenson, Mary J., Wellik, Linda E., Shing, Jennifer C., Peterson, Kevin L., Flatten, Karen S., Hess, Allan D., Smith, B. Douglas, Karp, Judith E., Barr, Sharon, Witzig, Thomas E., Kaufmann, Scott H.

“…The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which…”
Get full text

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia by Al‐Kali, Aref, Aldoss, Ibrahim, Atherton, Pamela J., Strand, Carrie A., Shah, Bijal, Webster, Jonathan, Bhatnagar, Bhavana, Flatten, Karen S., Peterson, Kevin L., Schneider, Paula A., Buhrow, Sarah A., Kong, Jianping, Reid, Joel M., Adjei, Alex A., Kaufmann, Scott H.

“…Background Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib…”
Get full text

Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis by Dai, Haiming, Meng, X. Wei, Lee, Sun-Hee, Schneider, Paula A., Kaufmann, Scott H.

“…The release of cytochrome c from mitochondria, which leads to activation of the intrinsic apoptotic pathway, is regulated by interactions of Bax and Bak with…”
Get full text

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation by Ding, Husheng, Hackbarth, Jennifer, Schneider, Paula A., Peterson, Kevin L., Meng, X. Wei, Dai, Haiming, Witzig, Thomas E., Kaufmann, Scott H.

“…The mechanism of cytotoxicity of farnesyltransferase inhibitors is incompletely understood and seems to vary depending on the cell type. To identify potential…”
Get full text

Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance by HAIMING DAI, HUSHENG DING, WEI MENG, X, LEE, Sun-Hee, SCHNEIDER, Paula A, KAUFMANN, Scott H

“…Bcl-2 is phosphorylated on Ser(70) after treatment of cells with spindle poisons. On the basis of effects observed in cells overexpressing Bcl-2 S70E or S70A…”
Get full text

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma by Correia, Cristina, Schneider, Paula A., Dai, Haiming, Dogan, Ahmet, Maurer, Matthew J., Church, Amy K., Novak, Anne J., Feldman, Andrew L., Wu, Xiaosheng, Ding, Husheng, Meng, X. Wei, Cerhan, James R., Slager, Susan L., Macon, William R., Habermann, Thomas M., Karp, Judith E., Gore, Steven D., Kay, Neil E., Jelinek, Diane F., Witzig, Thomas E., Nowakowski, Grzegorz S., Kaufmann, Scott H.

“…Follicular lymphoma (FL), an indolent neoplasm caused by a t(14;18) chromosomal translocation that juxtaposes the BCL2 gene and immunoglobulin locus, has a…”
Get full text

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells by Ding, Husheng, McDonald, Jennifer S, Yun, Seongseok, Schneider, Paula A, Peterson, Kevin L, Flatten, Karen S, Loegering, David A, Oberg, Ann L, Riska, Shaun M, Huang, Shengbing, Sinicrope, Frank A, Adjei, Alex A, Karp, Judith E, Meng, X Wei, Kaufmann, Scott H

“…Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism…”
Get full text

AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death by Jia, Jia, Ji, Wenbo, Saliba, Antoine N., Csizmar, Clifford M., Ye, Kaiqin, Hu, Lei, Peterson, Kevin L., Schneider, Paula A., Meng, X. Wei, Venkatachalam, Annapoorna, Patnaik, Mrinal M., Webster, Jonathan A., Smith, B. Douglas, Ghiaur, Gabriel, Wu, Xinyan, Zhong, Jun, Pandey, Akhilesh, Flatten, Karen S., Deng, Qingmei, Wang, Hongzhi, Kaufmann, Scott H., Dai, Haiming

“…BH3 mimetics, including the BCL2/BCLX L /BCLw inhibitor navitoclax and MCL1 inhibitors S64315 and tapotoclax, have undergone clinical testing for a variety of…”
Get full text

Measurement of BH3-only protein tolerance by Dai, Haiming, Ding, Husheng, Peterson, Kevin L, Meng, X Wei, Schneider, Paula A, Knorr, Katherine L B, Kaufmann, Scott H

“…The BCL2 family of proteins regulates cellular life and death decisions. Among BCL2 family members, BH3-only proteins have critical roles by neutralizing…”
Get full text

Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression by Meng, X.Wei, Koh, Brian D., Zhang, Jin-San, Flatten, Karen S., Schneider, Paula A., Billadeau, Daniel D., Hess, Allan D., Smith, B.Douglas, Karp, Judith E., Kaufmann, Scott H.

“…Recombinant human tumor necrosis factor-α-related apoptosis inducing ligand (TRAIL), agonistic monoclonal antibodies to TRAIL receptors, and small molecule…”
Get full text

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells by Yun, Seongseok, Vincelette, Nicole D., Knorr, Katherine L.B., Almada, Luciana L., Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Dai, Haiming, Pratz, Keith W., Hess, Allan D., Smith, B.Douglas, Karp, Judith E., Hendrickson, Andrea E.Wahner, Fernandez-Zapico, Martin E., Kaufmann, Scott H.

“…The mammalian target of rapamycin (mTOR), a kinase that regulates proliferation and apoptosis, has been extensively evaluated as a therapeutic target in…”
Get full text

CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia by Ding, Husheng, Vincelette, Nicole D, McGehee, Cordelia D, Kohorst, Mira A, Koh, Brian D, Venkatachalam, Annapoorna, Meng, X Wei, Schneider, Paula A, Flatten, Karen S, Peterson, Kevin L, Correia, Cristina, Lee, Sun-Hee, Patnaik, Mrinal, Webster, Jonathan A, Ghiaur, Gabriel, Smith, B Douglas, Karp, Judith E, Pratz, Keith W, Li, Hu, Karnitz, Larry M, Kaufmann, Scott H

“…Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible…”
Get full text